Cite

    Mei, H. et al. (2022). Dose tapering to withdrawal stage and long‐term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open‐label extension study. Journal of thrombosis and haemostasis. pp. 716-728. [Online].